TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00349167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR-104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT04114292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tauroursoursodeoxycholic acid, brand name Tudcabil
Description: Dosed in capsules containing 250 or 500mg of TUDCA for a total dose of 1.75-2g/day
Study: NCT03449498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qualitative functional therapy
Description: Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Six functional activities focusing on lower limbs and trunk are performed: walking, stair climbing, balance, transfers, trunk control, and Wii (combination of functional activities in sitting and/or standing). A group of clinical experts composes a set of exercises for each of these activities, however individual adaptations according to the needs and abilities of the child can be still be done. Quality of movement (alignment, weightshift, dissociation, coordination and stability) is hereby very important. The theme 'circus' is used to enhance the motivation of the children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional therapy
Description: Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Goals are set with the parents and the children. During the camp children work on obtaining these goals in a exclusively functional way.
Study: NCT02956954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (Agalsidase alpha (Replagal®))
Description: Patient treated with Enzyme replacement therapy as usual (Agalsidase alpha (Replagal®)). The treatment is prescribed in routine and not specially for the protocol

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging will be assessed every 6 months during 2 years

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging will be assessed every 6 months during 2 years
Study: NCT00907348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LR-CHOP21
Description: FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14~SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14~THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14~FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days
Study: NCT00883662

Intervention type: DRUG
Intervention: Levonorgestrel (Mirena, BAY86-5028)
Description: Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
Study: NCT01467843

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: The Cognitive Behavioral Therapy Intervention will be delivered during 8 weekly classes each lasting 2 hours. The classes will be held at a conveniently located Group Health Facility.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: The Mindfulness Based Stress Reduction Classes will be delivered in 8 weekly classes each lasting 2 hours.
Study: NCT01262378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal plastic surgery
Description: Surgery for ABDOMINAL SUBCUTANEOUS FAT

Intervention type: PROCEDURE
Group type: OTHER
Intervention: abdominal plastic surgery
Description: Surgery for ABDOMINAL SUBCUTANEOUS FAT
Study: NCT00402649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Description: Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.
Study: NCT01040351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided aspiration of hydrosalpingeal fluid
Description: Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
Study: NCT00677651

Intervention type: PROCEDURE
Intervention: Adipose Biopsy
Description: Adipose tissue will be sampled from the abdomen and buttock

Intervention type: PROCEDURE
Intervention: Adipose Biopsy
Description: Adipose tissue will be sampled from the abdomen and buttock

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood will be sampled from an IV line

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood will be sampled from an IV line

Intervention type: RADIATION
Intervention: CT Scan
Description: Single image at the level of the liver

Intervention type: RADIATION
Intervention: CT Scan
Description: Single image at the level of the liver

Intervention type: RADIATION
Intervention: DEXA
Description: Whole body scan

Intervention type: RADIATION
Intervention: DEXA
Description: Whole body scan
Study: NCT01432249

Intervention type: DRUG
Intervention: Enbrel group
Description: will be decided by treating physicians
Study: NCT01999465

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard NMES device
Description: Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~* Rate(35 Hz)~* Width (300 us)~* Ch1 Ramp+ (2 seconds)~* On Time 1 (10 seconds)~* Ch1 Ramp - (2 seconds)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NMES device
Description: Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~* Rate(35 Hz)~* Width (48 us)~* Ch1 Ramp+ (0 seconds)~* On Time 1 (0 seconds)~* Ch1 Ramp - (0 seconds)
Study: NCT04798599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring and teleorientation
Description: Teleservice will be performed through a digital platform (Video for Health - V4H). The service will consist of: a) recognition of the condition identified in the pandemic period, including updates on medical history, current oral health condition, search for dental care in other units, need for referral, change of hygiene habits, b) realization of diet guidance, hygiene and other necessary habits, made from a situational recognition of such habits, c) targeting the needs presented, in which individualized counselling will be given seeking to meet the demand presented by that family nucleus. A dental form developed on the digital platform Google Forms will serve as a guide for the performance of the service and where the collected data will be formally recorded. The guidelines, although individualized for the needs of each child, will follow a pre-defined and standardized structure and based on the best evidence available in the subject.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group - Waiting list
Description: No intervention (at least, until the time frame for outcome assessment)
Study: NCT01572116

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine with Epinephrine+ Normal saline
Description: PDL injection of 0/4 ml of lidocaine %2 with epinephrine,and Normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine with Epinephrine + sufentanil
Description: PDL injection of 0/4 ml lidocaine with epinephrine and0/4 ml sufentanil ( 0/04 μg)
Study: NCT04053868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL
Description: Electronic Cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco
Description: Tobacco Cigarette
Study: NCT02281643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm
Study: NCT00760019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salsalate
Description: 1.5 grams orally 3 times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study: NCT00366275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy, in vivo purging and autrotransplant
Description: 2-4 courses every 3 weeks with rituximab 375 mg/m\^2 on day 1, vincristine 1.4 mg/m\^2 on day 2 and cyclophosphamide 400 mg/m\^2 on days 2-6. Courses were started if granulocytes \>1.5 · 10\^9/l. The phase of peripheral blood stem cells (PBSC) mobilization coupled rituximab 375 mg/m\^2 on days 1 and 9 with high-dose cytarabine (AraC) 2 g/m\^2 every 12 hours on days 2 and 3. Granulocyte colony-stimulating factor (G-CSF)(5 mcg/kg/day subcutaneously) was administered from day 6. High-dose chemotherapy with autotransplant consisted of BEAM \[carmustine (BCNU), etoposide, Cytarabine (AraC), melphalan\] followed by the infusion of in vivo purged peripheral blood stem cells (PBSC) + 2 consolidation doses of rituximab 375 mg/m\^2 on days +14 and +21 after autotransplant.
Study: NCT01349868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT005 MDI
Description: PT005 MDI taken as two inhalations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT005 MDI
Description: PT005 MDI taken as two inhalations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT005 MDI
Description: PT005 MDI taken as two inhalations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
Description: Taken as 1 capsule. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate 24 μg (Foradil® Aerolizer®)
Description: Taken as 2 capsules. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Matching placebo to PT005 MDI taken as two inhalations
Study: NCT04427007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moisture Management Liner
Description: A prototype liner designed to reduce and/or remove moisture and heat that builds up on the limb.

Intervention type: DEVICE
Group type: OTHER
Intervention: ICE Socket Cooling System
Description: The ICE Socket Cooling System is a battery-powered cooling device for lower-limb amputees.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICE Socket Cooling System
Description: The ICE Socket Cooling System is a battery-powered cooling device for lower-limb amputees.
Study: NCT01786200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study: NCT03677830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Scheduled intravenous acetaminophen for post-operative pain to minimize opiate exposure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous saline will be administered at appropriate volume and schedule for control group as a placebo.
Study: NCT03370536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioInsight ECGI Mapping System
Description: The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation
Description: Empiric ablation (CFAE or linear ablation) is not permitted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)
Study: NCT02791984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluid challenge with 250 ml of Ringer Lactate
Description: Fluid challenge with 250 ml of Ringer Lactate over less than 2 minutes, intra-venous, help by a syringe of 50 ml.~Measure of peak velocity before and after the fluid challenge
Study: NCT00522145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL647
Description: Daily dosing as a single oral agent at a dose of 300 mg supplied as 50-mg tablets
Study: NCT04096209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autograft mixed with xenograft bone
Description: Eligible patients will be randomized in equal proportions between control group (immediate implant placement without bone grafts in the jumping gap) and study group (immediate implant placement with a mixture of Xenograft and autogenous bone placed in the jumping gap).~All patients will be evaluated by proper history taking and thorough clinical and radio graphical examination and assessed according to the inclusion and exclusion criteria.~Patients of both groups will be subjected to Cone beam Computed tomography (CBCT).~Primary impression will be taken, a study model will then be poured and then waxing up will be performed.~Patients will be instructed to rinse with chlorhexidine 0.1% mouthwash. Articaine 4% (1:100,000) local anesthesia will be given to the patient. Atraumatic extraction of the tooth or remaining root using No. 15c lancet and periotome
Study: NCT01370720

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Recoclix
Description: tablets; 200 mg PEA+20 mg polydatin; 2 tablets/day; 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, 2tablets/day, 12 weeks
Study: NCT04628637

Intervention type: OTHER
Intervention: Serum protein level analysis
Description: Serum GRP78 levels of the subjects were measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human Glucose Regulated Protein 78 (GRP78) ELISA Kit, Sun Long, SL2048Hu, China), as per the manufacturer's protocol. The detection rate of this kit is 16 pg/mL.

Intervention type: OTHER
Intervention: Serum protein level analysis
Description: Serum GRP78 levels of the subjects were measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human Glucose Regulated Protein 78 (GRP78) ELISA Kit, Sun Long, SL2048Hu, China), as per the manufacturer's protocol. The detection rate of this kit is 16 pg/mL.

Intervention type: OTHER
Intervention: Serum protein level analysis
Description: Serum GRP78 levels of the subjects were measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human Glucose Regulated Protein 78 (GRP78) ELISA Kit, Sun Long, SL2048Hu, China), as per the manufacturer's protocol. The detection rate of this kit is 16 pg/mL.
Study: NCT03027362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) and medication
Description: Sixteen sessions over 14 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation and medication
Study: NCT04090008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRP gel
Description: The PRP gel is applied on the ulcer twice per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline dressing
Description: Normal saline is used for dressing of the ulcer twice a week
Study: NCT02281370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: White to off white bi-convex round tablets containing eltrombopag 50 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: White to off white bi-convex round tablets containing eltrombopag 50 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: White to off white bi-convex round tablets containing eltrombopag 50 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Soft gelatine capsule containing cyclosporine 100 mg for oral administration. Cyclosporine will be administered at the doses of 200 mg (2 x 100 mg capsules) or 600 mg (6 x 100 mg capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Soft gelatine capsule containing cyclosporine 100 mg for oral administration. Cyclosporine will be administered at the doses of 200 mg (2 x 100 mg capsules) or 600 mg (6 x 100 mg capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Soft gelatine capsule containing cyclosporine 100 mg for oral administration. Cyclosporine will be administered at the doses of 200 mg (2 x 100 mg capsules) or 600 mg (6 x 100 mg capsules)
Study: NCT03357731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNO Donor
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNO Donor
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNO Donor
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNO Donor
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNO Donor
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNO Donor
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Description: Infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Infusion
Study: NCT01417195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bravelle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menopur

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menopur
Study: NCT00338039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500 mg/m\^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Induction Therapy: 1 gm/m\^2 over 100 minutes every 2 weeks +/-1 day for 4 doses.~Chemotherapy Maintenance: 1 gm/m\^2/week over 100 minutes weekly for 3 weeks then 1 week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Induction Chemotherapy: 100 mg/m\^2 over 120 minutes every 2 weeks +/-1 day for 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m\^2 by mouth (PO) twice daily Monday-Friday throughout radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
Study: NCT04248101

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double Ligation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Silver Nitrate
Study: NCT04156971

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: stage-based lifestyle modification intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stage-based lifestyle modification intervention
Study: NCT04092712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-CTP-543
Description: Single dose of radiolabeled CTP-543 (approximately 75 μCi) administered as an oral solution
Study: NCT00677820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine
Description: Trivalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 ml of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10:7 FFU (fluorescent focus units) of each of three cold-adapted, attenuated, 6:2 reassortant influenza strains A/South Dakota/6/07 (H1N1), A/Uruguay/716/07 (H3N2), and B/Florida/4/2006.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in intranasal sprayers containing 0.5 ml of sucrose-phosphate buffer.
Study: NCT05246020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Docetaxel (60-75mg/m2) perfusion solution will be infused into the peritoneal cavity through the tubes within 24 hours after the laparoscopic evaluation. Then, perfusate containing cisplatin (75 mg/m2) will be infused 24 hours later. NHIPEC will be administered at 43°C for a duration of 60min. Saline solution (3000mL) will be used to dissolve the drug, and it will be heated and circulated at a flow rate of 300-500 mL/min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous chemotherapy
Description: Patients in the control group will receive three cycles of intravenous NACT. The regimen of intravenous NACT is docetaxel 60-75mg/m2 followed by carboplatin AUC 5 for a 21-day cycle.
Study: NCT01489670

Intervention type: DRUG
Intervention: bimatoprost 0.01% ophthalmic solution
Description: Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
Study: NCT02385981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stivax
Study: NCT02015442

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose